Search by keyword

Topics

Resource type

Year of publication

21 result(s) found, displaying 1 to 20 | Clear filters

National Tall Man Lettering List
2020
Guide, user guide or guidelines

The Commission has revised the National Tall Man Lettering List to include cloBAZam in the benzodiazepine class of medicines, based on the reporting of adverse events and near misses and its high similarity and likelihood of confusion with another benzodiazepine: CLONAZepam.

NSQHS Standards User Guide for Medication Management in Cancer Care - cover
NSQHS Standards User Guide for Medication Management in Cancer Care
2020
Guide, user guide or guidelines

This User Guide describes best practice strategies under each of the 28 specific actions to support organisations to deliver effective medication management in cancer services.

NSQHS Standards User Guide for Medication Management in Cancer Care for clinicians
2020
Guide, user guide or guidelines

The purpose of this guide is to provide clinicians with evidence-based strategies to support them to understand and fulfil their roles and responsibilities. It combines information from a range of existing guides and resources, including the National Safety and Quality Health Service Standards User Guide for Medication Management in Cancer Care.

COVID-19 Position Statement - Management of patients on oral anticoagulants during COVID-19
2020
Guide, user guide or guidelines

Last updated 27 August 2020

COVID-19 Position Statement - ACE inhibitors and ARBs in COVID-19
2020
Guide, user guide or guidelines

Last updated 28 April 2020

COVID-19 Position Statement - Managing a sore throat associated with COVID-19
2020
Guide, user guide or guidelines

Last updated 29 April 2020

COVID-19 Position Statement - Treatment in acute care, including oxygen therapy and medicines to support intubation
2020
Guide, user guide or guidelines

Last updated 15 May 2020

COVID-19 Position Statement - Nebulisation and COVID-19
2020
Guide, user guide or guidelines

Last updated 15 May 2020

COVID-19 Position Statement - Ongoing medicines management in high-risk patients
2020
Guide, user guide or guidelines

Last updated 28 April 2020

COVID-19 Position Statement - Clozapine in COVID-19
2020
Guide, user guide or guidelines

Last updated 28 April 2020

COVID-19 Position Statement - Managing fever associated with COVID-19
2020
Guide, user guide or guidelines

Last updated 29 April 2020

COVID-19 Position Statement - Medicines shortages and COVID-19
2020
Guide, user guide or guidelines

Last updated 28 April 2020

COVID-19 Position Statement - Ascorbic Acid: Intravenous high dose in COVID-19
2020
Guide, user guide or guidelines

Last updated 12 May 2020

COVID-19 Position Statement - Managing intranasal administration of medicines for patients during COVID-19
2020
Guide, user guide or guidelines

Last updated 19 May 2020

Principles for the safe selection and storage of medicines: Guidance on the principles and survey tool
2020
Guide, user guide or guidelines

This guidance outlines strategies and principles developed to address safe selection and storage of all medicines, including look-alike, sound-alike (LASA) medicines.

Principles for the safe selection and storage of medicines: Survey tool
2020
Guide, user guide or guidelines

This survey tool provides Australian health service organisations with a set of 14 principles supported by a variety of risk reduction strategies. The tool should be used in conjunction with the Principles for the safe selection and storage of medicines – Guidance and survey tool.

Conserving Medicines - Guidance for Health Service Organisations
Position Statement - Conserving medicines
2020
Guide, user guide or guidelines

Last updated 21 August 2020

Intravenous Medicines Administration - Position Statement
Position Statement - Intravenous medicines administration in the event of an infusion pump shortage
2020
Guide, user guide or guidelines

Date of revision: 25 August 2020

Front cover of the Active ingredient prescribing user guide
Active ingredient prescribing user guide
2020
Guide, user guide or guidelines

This user guide supports prescribers to prescribe medicines by the active ingredient with best practice guidance for specification of brand.

Front cover fo the List of Medicines for Brand Consideration for active ingredient prescribing
List of Medicines for Brand Consideration (LMBC)
2020
Guide, user guide or guidelines

The Active ingredient prescribing – User guide for Australian prescribers supports prescribers to prescribe medicines by the active ingredient with best practice guidance for specification of brand. Principles are outlined in the user guide to determine when prescribers should consider brand name specification if clinically necessary. Specifying the brand name may be necessary to support safe and quality use of a medicine where consumer harm could result from switching between medicine brands or to ensure prescriber instructions are suitable for the dispensed medicine.

This List of Medicines for Brand Consideration includes medicines prescribers should consider prescribing by brand as well as active ingredient, if clinically necessary for the treatment of their patient. For example, in situations where formulations are not interchangeable due to variations in delivery of the active ingredient, prescribers should consider specification by brand for patient safety.